- Veteran Securities Attorney Joins Management to Guide M&A Initiatives, SEC Regulatory Affairs, and Generex
Up-listing
MIRAMAR, FL, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (OTCQB: GNBT)
is pleased to announce that Marshal Schictman, Esq. has joined the executive management team as Executive Vice President, General
Counsel to oversee the company’s M&A activities, regulatory affairs and SEC filings. Mr. Schictman has practiced law for over
16 years, with wide-ranging expertise in the areas of corporate, securities, and finance law, primarily in the areas of capital
markets and securities trading. He has acted as general counsel for public and private companies, performing litigations and
corporate transactional work, both domestically and internationally.
Mr. Schictman brings a wealth of experience in capital markets, serving as outside general securities counsel for
several public companies, handling securities filings, capital transactions, financing, administrative hearings and inquiries,
contested proxies, and Board and annual meetings.
Mr. Schictman attained his undergraduate degree from Boston University, his law degree from Touro Law Center, his
MBA in Finance from Long Island University, his LLM in International Taxation and Offshore Financial Centers from St. Thomas
University, and studied for passing the bar at Oxford-Brookes University in the United Kingdom. He is licensed to practice in the
State of New York, 2nd Circuit Court of Appeals for the State of New York, the Eastern and Southern Federal Districts for the State
of New York, and he maintains a current practicing certificate in England and Wales.
“I have worked with Marshal for several years, and he has earned his reputation as an expert in SEC regulations
and public company fiduciary matters,” said Joseph Moscato, CEO of Generex. “I am very proud to have such a high caliber executive
join our outstanding management team as we execute on our strategic plan to the benefit of our shareholders.”
Mr. Schictman provided his thoughts on joining the Generex executive management team, “I am excited and honored
that Joe has asked me to be part of the exciting future of Generex. I look forward to advancing the company’s strategy as an
integrated healthcare holding company as we build corporate value through strategic acquisitions and operational excellence.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric
care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that
extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to
improve the patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immuno-oncology assets, medical devices, and diagnostics, the
Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources
of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical
laboratory, and medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with
a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same
subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate,"
"would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or
current facts. Forward-looking statements frequently are used in discussing potential product applications, potential
collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating
matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a
broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties
include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which
should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or
events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection
of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contact: Generex Biotechnology Corporation Joseph Moscato 646-599-6222 Todd Falls 1-800-391-6755 Extension 222 investor@generex.com
